Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study.
Mileva M, Van Bogaert C, Marin G, Danieli R, Artigas C, Levillain H, Ameye L, Taraji-Schiltz L, Stathopoulos K, Wimana Z, Hendlisz A, Flamen P, Karfis I. Mileva M, et al. Among authors: karfis i. Clin Nucl Med. 2024 Sep 1;49(9):847-853. doi: 10.1097/RLU.0000000000005330. Epub 2024 Jun 19. Clin Nucl Med. 2024. PMID: 38914016 Clinical Trial.
[18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
Chan DL, Hayes AR, Karfis I, Conner A, Mileva M, Bernard E, Schembri G, Navalkissoor S, Gnanasegaran G, Pavlakis N, Marin C, Vanderlinden B, Flamen P, Roach P, Caplin ME, Toumpanakis C, Bailey DL. Chan DL, et al. Among authors: karfis i. J Nucl Med. 2024 Feb 1;65(2):185-191. doi: 10.2967/jnumed.123.266346. J Nucl Med. 2024. PMID: 38164579 Free PMC article.
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels C, Vanderlinden B, Paesmans M, Ameye L, Critchi G, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, Hendlisz A, Flamen P, Karfis I. Mileva M, et al. Among authors: karfis i. J Nucl Med. 2024 Feb 1;65(2):236-244. doi: 10.2967/jnumed.123.265987. J Nucl Med. 2024. PMID: 38164576 Clinical Trial.
PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Shagera QA, Karfis I, Kristanto P, Spyridon S, Diamand R, Santapau A, Peltier A, Roumeguère T, Flamen P, Artigas C. Shagera QA, et al. Among authors: karfis i. J Nucl Med. 2023 Dec 1;64(12):1869-1875. doi: 10.2967/jnumed.123.265874. J Nucl Med. 2023. PMID: 37770114 Free article.
Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Delbart W, Marin G, Stamatopoulos B, de Wind R, Sirtaine N, Demetter P, Vercruyssen M, Woff E, Karfis I, Ghanem GE, Flamen P, Wimana Z. Delbart W, et al. Among authors: karfis i. Cancers (Basel). 2023 Apr 17;15(8):2332. doi: 10.3390/cancers15082332. Cancers (Basel). 2023. PMID: 37190261 Free PMC article.
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score.
Chan DL, Hayes AR, Karfis I, Conner A, Furtado O'Mahony L, Mileva M, Bernard E, Roach P, Marin G, Pavlakis N, Schembri G, Gnanasegaran G, Marin C, Vanderlinden B, Navalkissoor S, Caplin ME, Flamen P, Toumpanakis C, Bailey DL. Chan DL, et al. Among authors: karfis i. Br J Cancer. 2023 Feb;128(4):549-555. doi: 10.1038/s41416-022-02061-5. Epub 2022 Nov 25. Br J Cancer. 2023. PMID: 36434154 Free PMC article.
30 results